Botulinumtoxins in the Management of Movement Disorders: Laxman Bahroo, DO


The professor of neurology and residency program director at MedStar Georgetown University Hospital spoke to the evolution of the utility of botulinumtoxins in the treatment of patients with Parkinson and other movement disorders. [WATCH TIME: 4 minutes]

WATCH TIME: 4 minutes

“I think this is an exciting class. If you look at the possibilities where this class of medications can be utilized, I think this class will continue to grow, with newer formulations and formulations that give us more options—maybe something that will give us longer duration. The newer indications will also be important.”

At the 2nd Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress, held by the PMD Alliance from June 8 to 11, 2023, in Washington, DC, a masterclass series of sessions was put on by a group of expert injectors who are movement disorder specialists. This group, including Laxman Bahroo, DO, professor of neurology and residency program director at MedStar Georgetown University Hospital, shared their insight across these 3 classes on the usefulness of the botulinumtoxin class in the management of movement disorders.

Botulinumtoxins are a common class of injectable medications that have grown in use after originally approved for a limited number of indications. Since its early use, the class has expanded to include a variety of treatment purposes, making them a useful option for physicians who are seeking to address the symptoms and disorders that patients experience—ranging from sialorrhea to migraine. Bahroo and several colleagues covered everything from the basics of botulinumtoxin use to hands on practice with injections while at ATMRD this year, all with a goal of educating on the usefulness of these therapies for addressing a range of symptoms that are relevant to Parkinson disease (PD) care.

At the meeting, Bahroo spoke with NeurologyLive® to summarize these classes and the potential benefits of these medications, as well as to offer an overview of some of the challenges associated with their regular use—both from a clinical and reimbursement perspective. He finished by speaking to the future expansion of this class of medications and his hopes for their growing potential to come to fruition for patients and physicians.

Click here for more coverage of ATMRD 2023.

Related Videos
Ro'ee Gilron, PhD
Monica Verduzco-Gutierrez, MD
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
Michael Levy, MD, PhD
Michael Levy, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.